The cardiovascular portfolio grew mid-single-digits, with cardiac ablation solutions reporting 22% growth, driven by the Pulse Field Ablation (PFA) products, Affera and PulseSelect. Management ...

I'm Ryan Weispfenning, vice president and head of Medtronic investor relations, and I appreciate that you're joining us for our fiscal '25 third-quarter video earnings webcast. Before we go inside to ...

I would like to welcome everyone to The Chemours Company fourth-quarter 2024 results conference call. [Operator instructions] I would like to remind everyone that this conference call is being ...

Medtronic (MDT) stock slips as the company reaffirms full-year outlook after delivering mixed financial for Q3 fiscal 2025.

The Chemours Company (“Chemours” or “the Company”) (NYSE: CC), a global chemistry company with leading market positions in Thermal & Specialized Solutions (“TSS”), Titanium Technologies (“TT”), and ...

Medtronic plc (NYSE: MDT) today announced financial results for its third quarter (Q3) of fiscal year 2025 (FY25), which ended January 24, 2025.